NodThera appoints Sanofi alum as new President and CEO

NodThera appoints Sanofi alum as new President and CEO
Adam Keeney

Biotech NodThera has appointed Sanofi and Johnson & Johnson alum Adam Keeney as its new President and Chief Executive Officer.

Alan Watt, who has been Chief Scientific Officer and acting as interim Chief Executive Officer of the Company since its inception, will now resume his role as full-time CSO.

Mr Keeney joins NodThera from Sanofi Genzyme, where he served as Global Head of Sanofi Genzyme Business Development.

Previously, he worked at Johnson & Johnson where he held a number of roles with increasing responsibility eventually becoming Site Head of the Johnson & Johnson California Innovation Centre.

“I believe that NodThera’s next generation approach has the potential to bring new treatment options to patients across a wide range of therapeutic areas,” said Mr Keeney.

“With offices in both the UK and the US, NodThera is establishing a truly global business, well positioned to push the frontiers of inflammation research with access to the very best talent in the field.”